SS18-like protein 2 (SS18L2)

SS18-like protein 2 (SS18L2) is a human protein encoded by the SS18L2 gene, located on chromosome 3[5]. It is a paralog of SS18, a gene involved in oncogenic fusions in synovial sarcoma, but SS18L2 itself is not a common fusion partner. SS18L2 acts as a transcriptional coregulator, likely influencing chromatin remodeling through interaction with other nuclear proteins, such as members of the SWI/SNF complex[2][4]. Its structure is intracellular, and its biological role has parallels to other synovial sarcoma translocation family proteins. While associated with sarcoma by sequence homology, there is no evidence SS18L2 is currently a direct therapeutic target, nor are drugs or biomarkers established for it. Expression of SS18L2 may play a role in transcription regulation and cell differentiation, and it is studied mainly in the context of its relationship to the chromatin remodeling machinery and synovial sarcoma pathogenesis, not as an independent clinical or pharmacological target[2][4][7]. It is annotated as a protein-coding gene with disease association limited to sarcoma and functional analogies to the synovial sarcoma gene SS18[1][3]. SS18L2 is not classified as a receptor, enzyme, transporter, or typical drug target but as a nuclear protein related to chromatin regulation complexes[2][6]. Interacting proteins are primarily transcriptional or chromatin regulation factors (e.g., SSX family, SMARCA4), not pharmaceutical agents[2]. No evidence supports its use in clinical biomarker panels or as a direct drug target in existing drug libraries[1][2]. If you are seeking information for classic drug target mapping, SS18L2 does not meet conventional criteria (e.g., not a receptor, enzyme, transporter, or direct disease driver amenable to pharmacological targeting)[1][2][7].

Other names

SS18L2KIAA-isoSYT homolog 2synovial sarcoma translocation gene on chromosome 18-like 2